Nature Medicine, Published online: 16 April 2026; doi:10.1038/s41591-026-04340-7
In this phase 1/2 trial, patients with Ewing sarcoma received trabectedin and low-dose irinotecan at concentrations known to inhibit the activity of the transcription factor EWS::FLI1, leading to encouraging clinical response rates.
